Kidney disease treatment in 2026 may include medicines such as SGLT2 inhibitors, blood pressure medicines, finerenone, and GLP 1 based therapies. Treatment choices depend on kidney function, diabetes, blood pressure, cardiovascular risk, and other factors. A nephrologist can assess individual needs and explain potential benefits, risks, and monitoring requirements.
Kidney disease treatment continues to change as research provides more information about protecting kidney function and reducing cardiovascular risks. In 2026, nephrologists may consider several medication categories depending on kidney function, the underlying cause, blood pressure, diabetes, urine albumin levels and overall health. SGLT2 inhibitors, GLP 1 receptor agonists, ACE inhibitors, ARBs and finerenone may have roles for certain patients. Treatment is individualized because kidney disease can develop and progress differently from one person to another. This guide explains commonly discussed treatment approaches, what factors can influence medication choices and why regular monitoring remains important for people with chronic kidney disease.
Kidney disease treatment is not based on one universal prescription. In 2026, medical guidance increasingly focuses on protecting kidney function while also addressing blood pressure, diabetes, cardiovascular risk and other related conditions. The American Diabetes Association recommends kidney and cardiovascular protective therapies for appropriate people with type 2 diabetes and chronic kidney disease.
Before recommending medication, a nephrologist generally considers kidney function, urine albumin, blood pressure, diabetes status, other medical conditions and the rate at which kidney function is changing. These factors can influence which medicines are appropriate and how closely a person should be monitored.
Common areas considered include:
For people with diabetes and albuminuria or hypertension, ACE inhibitors or ARBs may be used when appropriate. The 2026 ADA guidance also notes that combining an ACE inhibitor and ARB should generally be avoided because of increased risks without demonstrated additional benefit.
SGLT2 inhibitors have become an important part of treatment discussions for certain people with chronic kidney disease. These medicines were initially developed for blood glucose management, but research has demonstrated kidney and cardiovascular benefits that extend beyond glucose lowering.
The 2026 ADA Standards of Care recommend an SGLT2 inhibitor with demonstrated benefit for people with type 2 diabetes and CKD, with initiation generally recommended when eGFR is at least 20 mL/min/1.73 m².
Important points include:
GLP 1 receptor agonists are another medication group increasingly discussed in kidney disease care, particularly among people who have type 2 diabetes and CKD. The 2026 ADA guidance recommends GLP 1 therapies with demonstrated benefit for reducing kidney disease progression and cardiovascular risk in appropriate patients.
These treatments may be considered based on several factors:
Research involving semaglutide has also provided evidence of kidney and cardiovascular benefits in people with type 2 diabetes and CKD. However, treatment decisions should still be individualized rather than based on one study or medication.
Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that may be considered for certain adults with type 2 diabetes, CKD and albuminuria. The 2026 ADA guidance identifies finerenone as the nonsteroidal MRA with demonstrated kidney and cardiovascular benefits in this setting.
Doctors may consider factors such as:
Because finerenone can affect potassium levels, monitoring is an important part of treatment when it is prescribed.
Modern kidney disease management can involve more than one protective approach. Different medications work through different mechanisms, so a nephrologist may consider combination treatment when it is suitable for an individual's circumstances.
For example, the 2026 ADA guidance discusses the potential use of an SGLT2 inhibitor together with finerenone in selected adults with type 2 diabetes, albuminuria and appropriate kidney function.
A treatment plan may therefore involve:
Not every person needs every medication. The appropriate combination depends on individual medical circumstances.
Medication selection is only one part of kidney disease management. Regular monitoring can help doctors understand whether kidney function is stable and whether treatment remains appropriate.
Depending on the individual situation, monitoring may include:
The 2026 guidance emphasizes individualized treatment and reassessment of kidney and cardiovascular risk over time.
Medicines are only one component of chronic kidney disease management. Healthy lifestyle habits can complement medical treatment and may help address risk factors associated with kidney and cardiovascular health.
Helpful areas to discuss with a healthcare professional include:
Lifestyle recommendations should also be individualized, particularly when kidney disease is advanced or other medical conditions are present.